Immunoglobulin G4-related sclerosing disease
MONDO:0017287A recently described mass-forming lesion that occurs in the pancreas, submandibular glands, lacrimal glands, lymph nodes, and hepatobiliary tract. It is characterized by the presence of marked tissue sclerosis and infiltration by numerous plasma cells. The plasma cells show immunohistochemical staining for IgG4 and the serum IgG4 levels are often increased.
Also known as: IgG4-RD, IgG4-related disease, IgG4-related sclerosing disease, IgG4-related systemic disease, immunoglobulin G4-related sclerosing disease, IgG4-associated disease, IgG4-positive multiorgan lymphoproliferative syndrome, IgG4-related autoimmune disease
69 clinical trials for this condition and its sub-types, 30 tagged with Immunoglobulin G4-related sclerosing disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Immunoglobulin G4-related sclerosing disease
-
Autoimmune pancreatitis 3 trials
2 sub-types
- Autoimmune pancreatitis type 1 0 trials
- Autoimmune pancreatitis type 2 0 trials
-
IgG4-related kidney disease 1 trial
-
1 sub-type
- Fibrosclerosis, multifocal 0 trials
-
IgG4-related aortitis 0 trials
-
IgG4-related mediastinitis 0 trials
-
IgG4-related mesenteritis 0 trials
-
IgG4-related ophthalmic disorder 0 trials
1 sub-type
-
IgG4-related pachymeningitis 0 trials
-
IgG4-related sclerosing cholangitis 0 trials
-
IgG4-related thyroid disease 0 trials
-
Cutaneous pseudolymphoma 0 trials
-
Eosinophilic angiocentric fibrosis 0 trials
-
Primary cutaneous plasmacytosis 0 trials
-
Can inhaled cell vesicles soothe damaged lungs in autoimmune disease?
Disease control Not yet recruitingThis early-phase trial tests a nebulized therapy called UC-EVs, derived from human umbilical cord cells, in adults with immune-mediated inflammatory diseases (such as IgG4-related disease or systemic sclerosis) that affect the lungs. Participants inhale the vesicles daily for 7 d…
Early phase 1 • Sponsor: Qiubai Li • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can engineered immune cells tame a stubborn autoimmune disease?
Disease control Not yet recruitingThis trial tests a single infusion of BCT301, a cell therapy made from stem cells that are engineered to target the immune system, in 6 adults with IgG4-related disease that has not improved with standard treatment. The main goal is to check whether the infusion is safe and toler…
Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug trial aims to tame rare inflammatory disease in kids
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 15 children aged 2 to 17 who have IgG4-related disease, a rare condition that causes swelling and damage in organs. The drug is given through an IV and works by lowering certain immune cells to reduce inflammation. Researchers will c…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could stem cells plus supercharged immune cells tame autoimmune disease?
Disease control Not yet recruitingThis early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Fetal stem cells aim to tame immune chaos
Disease control Not yet recruitingThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
A steroid-sparing strategy for IgG4-related disease: lenalidomide put to the test
Disease control Not yet recruitingThis phase III trial tests whether lenalidomide, an immune-modulating drug, can prevent disease flares in people with IgG4-related disease who are in remission. Participants receive either lenalidomide or a placebo for 52 weeks while tapering off steroids. The goal is to see if l…
Phase 3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to stop IgG4 disease relapses without Long-Term steroids
Disease control Not yet recruitingThis study tests a drug called IMM0306 in 125 people with IgG4-related disease, a condition where the immune system attacks organs causing swelling and damage. The goal is to see if IMM0306 can prevent disease flare-ups and allow patients to safely stop taking steroids. Participa…
Phase 2/3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Early phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
Disease control Not yet recruitingThis early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New gene therapy trial targets tough autoimmune conditions
Disease control Not yet recruitingThis early-stage study tests a new treatment called LVIVO-TaVec400 in 44 people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard therapies. The main goals are to check the treatment's safety and find the rig…
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug STR-P004 aims to tame immune attacks on kidneys
Disease control Not yet recruitingThis early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…
Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on rare autoimmune disease
Disease control Not yet recruitingThis early-phase study tests a new treatment called KN5601, which uses specially engineered natural killer (NK) cells to target and destroy disease-causing immune cells in people with relapsed or refractory IgG4-related disease. The trial will enroll 18 adults and primarily check…
Early phase 1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
A finger prick instead of a needle: could At-Home blood tests match hospital accuracy?
Diagnosis Not yet recruitingThis study tests whether blood samples collected at home using small capillary devices, like finger pricks, give the same results as traditional blood draws from a vein. Researchers will compare both methods in about 1,000 people with chronic conditions such as kidney disease, au…
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 20, 2026 00:00 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC